Hebei Changshan Biochem Pharma Net Asset Quality Index
Hebei Changshan Biochem Pharma net asset quality index. Hebei Changshan Biochem Pharma (300255) has a Net Asset Quality Index of 31.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.66 Billion minus total liabilities of CN¥3.18 Billion yields net assets of CN¥1.48 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Hebei Changshan Biochem Pharma book value and equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hebei Changshan Biochem Pharma (2008–2024)
Net asset quality index of Hebei Changshan Biochem Pharma from 2008 to 2024. This chart shows how Hebei Changshan Biochem Pharma's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 31.7%, representing net assets of CN¥1.48 Billion against total assets of CN¥4.66 Billion CNY. Check how strategically is Hebei Changshan Biochem Pharma's equity deployed to assess the company's strategic physical and investment asset allocation.
Hebei Changshan Biochem Pharma Net Asset Quality Index by Year (2008–2024)
Hebei Changshan Biochem Pharma net asset quality index by year from 2008 to 2024. The table below presents the year-by-year Net Asset Quality Index for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Hebei Changshan Biochem Pharma.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 34.0% | CN¥1.54 Billion | CN¥4.52 Billion | CN¥2.99 Billion | ▼ -5.2 pp |
| 2023 | 39.2% | CN¥1.80 Billion | CN¥4.60 Billion | CN¥2.80 Billion | ▼ -11.4 pp |
| 2022 | 50.6% | CN¥3.05 Billion | CN¥6.04 Billion | CN¥2.98 Billion | ▼ -8.6 pp |
| 2021 | 59.2% | CN¥3.07 Billion | CN¥5.19 Billion | CN¥2.12 Billion | ▼ -3.2 pp |
| 2020 | 62.4% | CN¥2.85 Billion | CN¥4.57 Billion | CN¥1.72 Billion | ▼ -6.6 pp |
| 2019 | 69.0% | CN¥2.72 Billion | CN¥3.94 Billion | CN¥1.22 Billion | ▲ +3.4 pp |
| 2018 | 65.6% | CN¥2.52 Billion | CN¥3.84 Billion | CN¥1.32 Billion | ▼ -3.4 pp |
| 2017 | 69.0% | CN¥2.44 Billion | CN¥3.53 Billion | CN¥1.09 Billion | ▼ -4.1 pp |
| 2016 | 73.1% | CN¥2.29 Billion | CN¥3.13 Billion | CN¥842.59 Million | ▲ +5.6 pp |
| 2015 | 67.5% | CN¥1.57 Billion | CN¥2.33 Billion | CN¥757.07 Million | ▼ -2.3 pp |
| 2014 | 69.8% | CN¥1.43 Billion | CN¥2.04 Billion | CN¥617.87 Million | ▼ -8.4 pp |
| 2013 | 78.1% | CN¥1.29 Billion | CN¥1.65 Billion | CN¥359.78 Million | ▼ -1.2 pp |
| 2012 | 79.4% | CN¥1.13 Billion | CN¥1.42 Billion | CN¥292.77 Million | ▼ -3.9 pp |
| 2011 | 83.2% | CN¥987.45 Million | CN¥1.19 Billion | CN¥198.78 Million | ▲ +32.3 pp |
| 2010 | 50.9% | CN¥219.39 Million | CN¥430.64 Million | CN¥211.25 Million | ▼ -8.8 pp |
| 2009 | 59.8% | CN¥159.19 Million | CN¥266.35 Million | CN¥107.15 Million | ▲ +12.2 pp |
| 2008 | 47.5% | CN¥93.43 Million | CN¥196.59 Million | CN¥103.16 Million | — |